Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
--------------------------------------------------------------------
Source: CNBC
Published: 2026-06-02 17:19 UTC+10:00
Section: General
Factuality Score: 100
Opinion Category: Neutral
Topics: Health, Economy & Finance, Financial Markets, Law & Courts, Drugs, Business & Economy, Crime & Justice
--------------------------------------------------------------------
Snippet:
Shares of French biotech Abivax tumbled 32% after it reported fresh data on its lead asset, a drug for ulcerative colitis, that showed a potential cancer risk in patients.
--------------------------------------------------------------------